Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic colorectal cancer: real-world evidence and prognostic insight.

ABSTRACT:

Background

BRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis and limited response to standard therapies. Recent clinical trials have explored the benefit of targeted therapies, but real-world data remain limited.

Methods

This retrospective study analyzed 36 patients with BRAF V600E-mutant mCRC who received first-line treatment between 2018 and 2024 at Taichung Veterans General Hospital. Patients were grouped by initial regimen: chemotherapy alone, chemotherapy plus anti-VEGF (bevacizumab), or chemotherapy combined with BRAF-targeted ± MEK inhibitors. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included objective response rate (ORR) and disease control rate (DC

SUBMITTER: Yeh CC 

PROVIDER: S-EPMC12318728 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature